Form4insider filings, from the source

SEC Form 3 · accession 0001493152-26-041688

Tonix Pharmaceuticals Holding Corp. · TNXP

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Thomas Englese
Officer — Chief Commercial Officer
Period of report
Sep 4, 2026
Accepted (ET)
Sep 8, 2026 · 7:05 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001430306

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stock, $0.001 par value per shareholding———694D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock OptionF1$16.51holding———Sep 9, 2025Sep 9, 2034Common Stock500—D
Stock OptionF2$8.05holding———Feb 25, 2026Feb 25, 2035Common Stock6,500—D
Stock OptionF3$20.18holding———May 13, 2026May 13, 2035Common Stock12,480—D
Stock OptionF4$14.29holding———Feb 24, 2027Feb 24, 2036Common Stock40,000—D

Explanation of responses